The following is a review of diagnostics related medical research worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Research News for October 2003
Researchers at the Royal Victoria Hospital, Montreal, QC and members of the Insulin Resistance Atherosclerosis Study have found that apolipoprotein B (apoB) appears to represent a better index of cardiac disease risk than does low-density lipoprotein cholesterol (LDLC) level. The study showed that patients who had a high triglyceride level and a high apoB were the ones more likely to have high blood sugar, more insulin resistance, more inflammation, and more prothrombogenic factors. The group suggests two choices for assessing patients at risk. 1) Include apoB as part of a routine panel, 2) run apoB when patients present with high triglyceride levels or a low HDL.
Scientists at the Weill Cornell School of Medicine, New York, have discovered a potential new marker to diagnose acute cardiac events in the ER. Myeloperoxidase (MPO) is made in white blood cells and produced when arteries are inflamed and have rupture-prone fatty deposits. The researchers suggest that MPO testing can detect the early stages of a heart attack. Further it could be used with other tests such as hsCRP as a marker of inflammation and cardiac disease risk. The study used the OXIS-MPO Oxidative Stress assay from Oxis International. Inc.
Recent guidelines released by the American Thoracic Society and the European Respiratory Society advise that all adults diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, adult-onset asthma, or unexplained liver disease should undergo genetic testing for alpha-1 antitrypsin deficiency. The rational for this is that alpha-1 antitrypsin deficiency can masquerade as COPD or asthma. The test allows clinicians to prescribe enzyme replacement therapy in addition to those required for COPD management.
Research News - September 2003
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: November 3, 2003